Type of Assessment:
Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma
Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates in the serosal layer of the pericardium. Currently, there are no specific guidelines for diagnosis and treatment in China and international countries for this disease,…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract Background: There…
Read MoreMetastatic pleural mesothelioma presenting as ulcerated submucosal colonic nodules
Journal of the American Association of Nurse Practitioners 2026 June 29 [Link] Shangwe Kiliaki, Kent Stevens Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy associated with poor prognosis. Although it typically spreads through local invasion, distant metastasis to the gastrointestinal tract is uncommon, and colonic involvement is particularly rare. We report a case…
Read MoreDual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
EJNMMI Research 2026 June 20 [Link] Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen Abstract Background: [18F]FDG PET/CT provides a non-invasive…
Read MoreAmivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
Journal of Thoracic Oncology 2026 June 20 [Link] Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Rohini Mopuri, Jennifer Ayers-Ringler, Lin Yang, Kim P Lauer, Katherine E R Smith, Yan W Asmann, Anja Roden, Farhad Kosari, Aaron S Mansfield Abstract Introduction: Diffuse pleural mesothelioma (DPM) is a lethal malignancy with no approved therapies directly targeting…
Read MoreCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MoreDevelopment and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
The Lancet, Oncology 2026 July [Link] Kevin B W Groot Lipman, Rianne Wittenberg, Mateus de Oliveira Taveira, Illaa Smesseim, Alexander M Th Schmitz , Thierry N Boellaard 2, Kalina Chupetlovska, Mohamed A Abdelatty, Liliana Petrychenko, Neeraj Jain, Francesco M Arico, Valerio Pugliese, Robin Cornelissen, Ties A Mulders, Fenneke Zwierenga, Birgitta I Hiddinga, Mena Shenouda, Samuel…
Read MoreExtracellular stressors change BBSome expression of benign mesothelial and primary pleural mesothelioma cells and affect cell adhesion and migration
Physiological Reports 2026 June [Link] Rajesh M Jagirdar, Erasmia Rouka, Eleanna Pitaraki, Sotirios I Sinis, Charalambos Varsamas, Eleftherios D Papazoglou, Lydia Giannakou, Panagiotis I Tzamalas, Ourania S Kotsiou, Anastasios Giannou, Chrissi Hatzoglou, Najib M Rahman, Konstantinos I Gourgoulianis, Sotirios G Zarogiannis Abstract Pleural mesothelial cells have a primary cilium (PC), a solitary sensory organelle facing…
Read MorePressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)
Journal of Thoracic Disease 2026 May 31 [Link] Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, Arjang Ruhparwar, Hayan Merhej, Patrick Zardo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel…
Read More
Skip to content